Trial Profile
A study of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- 17 May 2016 New trial record